Nonparametric Estimation of Lifetime and Disease Onset Distributions from Incomplete Observations

Dinse, Gregg E.; Lagakos, Stephen W.

doi:10.2307/2529872

Cited by 208 publications

(141 citation statements)

References 12 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…The cumulative effect of unfavorable genotypes identified in the single SNP analysis on recurrence and OS, was estimated by Cox model (Flynn, 2012). Kaplan-Meier curve and log-rank test were used to assess the differences in survival and time to recurrence between patients with different genotypes (Dinse and Lagakos, 1982). All P-values in this study were two-sided, and p<0.05 was considered to be significant.…”

Section: Discussionmentioning

confidence: 99%

Fatty Acid Synthesis Pathway Genetic Variants and Clinical Outcome of Non-Small Cell Lung Cancer Patients after Surgery

Jin¹,

Zhang²,

Guo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Fatty Acid Synthesis Pathway Genetic Variants and Clinical Outcome of Non-Small Cell Lung Cancer Patients after Surgery

Jin¹,

Zhang²,

Guo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Patient survival and LFS from the time of remission were computed by the product-limit method of Kaplan and Meier. 22 Survival curves for univariate analysis of each potential predictor were compared using the log-rank test. Prognostic factors for LFS and overall survival were evaluated by multivariate analysis using Cox's proportional-hazard regression analysis.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission

et al. 2003

View full text Add to dashboard Cite

In order to improve leukemia-free survival (LFS) without the treatment-related morbidity of allogeneic bone marrow transplantation or multiple prolonged cycles of consolidation chemotherapy, we evaluated the long-term outcome of autologous transplantation of peripheral blood progenitor cells (PBPCs) as postremission therapy in 129 patients aged 18-71 years (median 49 years) with newly diagnosed acute myelogenous leukemia (AML) in first complete remission (CR1). The median follow-up from remission for surviving patients was 62.2 months (range 3.7-127.9 months). A total of 57 patients were alive and leukemia free at the end of the study. The LFS and overall survival 5 years from remission were 40.2% (79.2%) and 41.4% (79.4%), respectively. The median LFS and overall survival are 17.3 and 23.3 months, respectively. Multivariate analysis identified age as the most significant predictor for both LFS and overall survival. Karyotype was also found to be predictive of outcome. Our results show that autologous transplantation of PBPC procured after a single cycle of highdose cytarabine-based consolidation chemotherapy for a population of adult patients with AML in CR1 produces a high likelihood of long-term LFS, offering a state of clinical minimal residual disease for the investigation of future therapeutic approaches.

show abstract

“…Therefore, survival time was calculated from the date of surgery until the last date of contact or death. Univariate analysis of survival data was performed according to Kaplan and Meier (22). The log-rank test was used to test the significance between the groups.…”

Section: Statistical Analysesmentioning

confidence: 99%

Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer

Schneider

Granzow

Warth

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: In recent years, immune therapeutic strategies against non–small cell lung cancer (NSCLC) based on tissue-derived biomarkers, for example PD1/PD-L1 (CD274), have evolved as novel and promising treatment options. However, the crosstalk between tumor and immune cells is poorly understood. Glycodelin (gene name PAEP), initially described in the context of pregnancy and trophoblastic implantation, is a secreted immunosuppressive glycoprotein with an as-of-yet largely unknown function in lung cancer. Experimental Design: In this study, we characterized the expression and role of glycodelin in NSCLC through mRNA and protein expression analyses, functional knockdown experiments, and correlations with clinicopathologic parameters. Results: Glycodelin mRNA expression was significantly elevated in tumors (n = 336) compared with matched normal tissue (P < 0.0001). Overall survival (OS) was significantly reduced in NSCLC with high glycodelin mRNA levels in women but not in men. Glycodelin was detected in the sera of patients, and the levels correlated with recurrence and metastatic disease. Knockdown of glycodelin with siRNAs in NSCLC cell lines resulted in significant upregulation of immune system modulatory factors such as PDL1, CXCL5, CXCL16, MICA/B, and CD83 as well as proliferation stimulators EDN1 and HBEGF. Furthermore, decreased migration of tumor cells was observed. Conclusions: Altogether, the comprehensive characterization of glycodelin in NSCLC provides strong support for its use as a biomarker with immune modulatory function. Clin Cancer Res; 21(15); 3529–40. ©2015 AACR.

show abstract

Nonparametric Estimation of Lifetime and Disease Onset Distributions from Incomplete Observations

Cited by 208 publications

References 12 publications

Fatty Acid Synthesis Pathway Genetic Variants and Clinical Outcome of Non-Small Cell Lung Cancer Patients after Surgery

Fatty Acid Synthesis Pathway Genetic Variants and Clinical Outcome of Non-Small Cell Lung Cancer Patients after Surgery

Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission

Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer

Contact Info

Product

Resources

About